These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 22753584)

  • 21. A behavioural Bayes approach to the determination of sample size for clinical trials considering efficacy and safety: imbalanced sample size in treatment groups.
    Kikuchi T; Gittins J
    Stat Methods Med Res; 2011 Aug; 20(4):389-400. PubMed ID: 20223784
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Statistical considerations for testing multiple endpoints in group sequential or adaptive clinical trials.
    Hung HM; Wang SJ; O'Neill R
    J Biopharm Stat; 2007; 17(6):1201-10. PubMed ID: 18027226
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adaptive designs for confirmatory clinical trials.
    Bretz F; Koenig F; Brannath W; Glimm E; Posch M
    Stat Med; 2009 Apr; 28(8):1181-217. PubMed ID: 19206095
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reducing overestimation of the treatment effect by interim analysis when designing clinical trials.
    Shimura M
    J Clin Pharm Ther; 2019 Apr; 44(2):243-248. PubMed ID: 30414384
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Flexible two-stage design with sample size reassessment for survival trials.
    Desseaux K; Porcher R
    Stat Med; 2007 Nov; 26(27):5002-13. PubMed ID: 17577242
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biostatistics in clinical trials: Part 2. Determining sample sizes for clinical trials.
    Ellenberg SS
    Oncology (Williston Park); 1989 Aug; 3(8):39-46; discussion 48, 51. PubMed ID: 2519197
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Small sample approach, and statistical and epidemiological aspects.
    Offringa M; van der Lee H
    Handb Exp Pharmacol; 2011; 205():181-202. PubMed ID: 21882112
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alternative designs of phase II trials considering response and toxicity.
    Jin H
    Contemp Clin Trials; 2007 Jul; 28(4):525-31. PubMed ID: 17428744
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Termination rules in therapeutic trials. Application of sequential methods in 2 clinical trials in hematology].
    Bénichou J; Lepage E; Chastang C
    Nouv Rev Fr Hematol (1978); 1987; 29(1):87-91. PubMed ID: 3473443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mid-course sample size modification in clinical trials based on the observed treatment effect.
    Jennison C; Turnbull BW
    Stat Med; 2003 Mar; 22(6):971-93. PubMed ID: 12627413
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Validation of surrogate endpoints in digestive oncology].
    Methy N; Bedenne L; Bonnetain F
    Bull Cancer; 2009 May; 96(5):591-5. PubMed ID: 19423485
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Meta-analyses and adaptive group sequential designs in the clinical development process.
    Jennison C; Turnbull BW
    J Biopharm Stat; 2005; 15(4):537-58. PubMed ID: 16022162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II clinical trials in oncology: strengths and limitations of two-stage designs.
    Schlesselman JJ; Reis IM
    Cancer Invest; 2006; 24(4):404-12. PubMed ID: 16777694
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does the Prentice criterion validate surrogate endpoints?
    Berger VW
    Stat Med; 2004 May; 23(10):1571-8. PubMed ID: 15122737
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A practical comparison of group-sequential and adaptive designs.
    Kelly PJ; Sooriyarachchi MR; Stallard N; Todd S
    J Biopharm Stat; 2005; 15(4):719-38. PubMed ID: 16022175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimising the design of phase II oncology trials: the importance of randomisation.
    Ratain MJ; Sargent DJ
    Eur J Cancer; 2009 Jan; 45(2):275-80. PubMed ID: 19059773
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of a mis-specification of the response rate under standard treatment in sequential clinical trials.
    Sébille V; Bellissant E
    Fundam Clin Pharmacol; 2005 Oct; 19(5):569-78. PubMed ID: 16176336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Surrogate endpoints].
    Hill C
    Bull Cancer; 1999; 86(7-8):622-4. PubMed ID: 10477379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical trial design in metastatic breast cancer: a commentary.
    Levine M
    Can J Oncol; 1995 Dec; 5 Suppl 1():40-2. PubMed ID: 8853523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.